Catalent behind Novo Nordisk's supply issues, says media
An FDA inspection gone awry at contract manufacturer Catalent's Belgian facility is allegedly behind Novo Nordisk's supply issues for its obesity drug, Wegovy, which was recently launched on the US market.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Concerns about acceptable production practices at Catalent's syringe filling facility is the reason why Novo Nordisk is now only expected to be able to fully meet Wegovy demand in the second half of 2022, according to media Bioprocess International.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
